Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.61 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | PHGDH | O43175 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049593 | 0.85 | DRD2 (0.59) | DRD2DRD3ADAMTS5NOTUMPHGDH | |
| SCHEMBL12947249 | 0.83 | MAPT (0.53) | ALDH1A1KMT2AMEN1MAPTMAPK1 | |
| SCHEMBL5763718 | 0.83 | DRD2 (0.60) | DRD2DRD3ADAMTS5NOTUMPHGDH | |
| SCHEMBL23467841 | 0.81 | DRD2 (0.55) | DRD2DRD3ADAMTS5NOTUMALDH1A1 | |
| SCHEMBL19002646 | 0.81 | DRD2 (0.55) | DRD2DRD3ADAMTS5NOTUMPHGDH | |
| SCHEMBL21169266 | 0.81 | DRD2 (0.55) | DRD2DRD3ADAMTS5NOTUMALDH1A1 | |
| SCHEMBL15800697 | 0.81 | DRD2 (0.79) | DRD2DRD3NOTUMPHGDH | |
| SCHEMBL12377877 | 0.80 | TSHR (0.61) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL19002446 | 0.80 | DRD2 (0.60) | DRD2DRD3ALDH1A1ESR1KMT2A | |
| SCHEMBL4776950 | 0.80 | ALDH1A1 (0.73) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | DRD2 4852/4885DRD3 4860/4885ADAMTS5 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.